Log In
Print
BCIQ
Print
Print this Print this
 

umeclidinium bromide/vilanterol (Anoro Ellipta, Laventair) (GSK573719/GSK642444)

Also known as: Anoro (GSK573719 (umeclidinium bromide)/GSK642444, GSK573719/vilanterol)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionFixed-dose inhaled dry powder formulation of a long-acting muscarinic antagonist (LAMA) and a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Muscarinic receptor ; Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist; Muscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat moderate chronic obstructive pulmonary disease (COPD) in patients who have or are at an increased risk for cardiovascular disease
Regulatory Designation

U.S. - Undisclosed Review (Treat chronic obstructive pulmonary disease (COPD));
EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD));
Japan - Standard Review (Treat chronic obstructive pulmonary disease (COPD));
Canada - Standard Review (Treat chronic obstructive pulmonary disease (COPD))

Partner

Theravance Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today